摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

p-Cyclohexyloxybenzaldehyd | 58236-90-1

中文名称
——
中文别名
——
英文名称
p-Cyclohexyloxybenzaldehyd
英文别名
4-(cyclohexyloxy)benzaldehyde;4-Cyclohexyloxybenzaldehyde
p-Cyclohexyloxybenzaldehyd化学式
CAS
58236-90-1
化学式
C13H16O2
mdl
——
分子量
204.269
InChiKey
DTVIRRALOYOZDS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:f04a27e611e18e5392a44f49dfa273fe
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    p-Cyclohexyloxybenzaldehyd 生成 ethyl (E)-3-(4-cyclohexyloxyphenyl)prop-2-enoate
    参考文献:
    名称:
    KUCHAR M.; BRUNOVA B.; REJHOLEC V.; ROUBAL Z.; GRIMOVA J.; NEMECEK, O., COLLECT. CZECH. CHEM. COMMUNS , 1975, 40, NO 11, 3545-3556
    摘要:
    DOI:
  • 作为产物:
    描述:
    环戊醇对羟基苯甲醛三苯基膦偶氮二甲酸二乙酯 作用下, 以 四氢呋喃 为溶剂, 反应 30.0h, 以34%的产率得到p-Cyclohexyloxybenzaldehyd
    参考文献:
    名称:
    Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
    摘要:
    本发明的一个目的是提供一种具有优异的抗真菌效果并在其物理性质、安全性和代谢稳定性方面优越的抗真菌剂。根据本发明,公开了以下式(I)所代表的化合物或其盐: 其中R1代表氢原子、卤素原子、氨基、C1-6烷基、C1-6烷氧基或C1-6烷氧基C1-6烷基;R2代表氢原子、C1-6烷基、氨基或二C1-6烷基氨基中的一个;X和Y中的一个是氮原子,另一个是氮原子或氧原子;环A代表一个5-或6-成员杂芳基环或可能具有卤素原子、1个或2个C1-6烷基的苯环;Z代表一个单键、一个亚甲基基、一个乙烯基、一个氧原子、一个硫原子、-CH2O-、-OCH2-、-NH-、-CH2NH-、-NHCH2-、-CH2S-或-SCH2-;R3代表氢原子、卤素原子、C1-6烷基、C3-8环烷基、C6-10芳基、一个5-或6-成员杂芳基、或可能具有1个或2个取代基的5-或6-成员非芳香杂环基;R4代表氢原子或卤素原子。
    公开号:
    US20070105904A1
点击查看最新优质反应信息

文献信息

  • Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
    申请人:CoCensys, Inc.
    公开号:US20020061886A1
    公开(公告)日:2002-05-23
    This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R 1 , R 21 , R 22 and R 23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R 22 and R 23 , together with the N, form a heterocycle; A 1 and A 2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR 24 , CR 25 R 26 , C(O), NR 24 C(O), C(O)NR 24 , SO, SO 2 or a covalent bond; where R 24 , R 25 and R 26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.
    这项发明涉及由式I表示的含有碳环和杂环取代的半卡巴松和硫代半卡巴松: 1 或其药学上可接受的盐或前药,其中: Y为氧或硫;R 1 ,R 21 ,R 22 和R 23 独立地为氢,烷基,环烷基,烯基,炔基,卤代烷基,芳基,氨基烷基,羟基烷基,烷氧基烷基或羧基烷基;或R 22 和R 23 ,与N一起形成一个杂环;A 1 和A 2 独立地为芳基,杂芳基,饱和或部分不饱和的碳环或饱和或部分不饱和的杂环,其中任何一个可选择地被取代;X为O、S、NR 24 、CR 25 R 26 、C(O)、NR 24 C(O)、C(O)NR 24 、SO、SO 2 或共价键;其中R 24 ,R 25 和R 26 独立地为氢,烷基,环烷基,烯基,炔基,卤代烷基,芳基,氨基烷基,羟基烷基,烷氧基烷基或羧基烷基。该发明还涉及利用含有碳环和杂环取代的半卡巴松和硫代半卡巴松治疗全脑和局部缺血后的神经损伤,治疗或预防神经退行性疾病如肌萎缩侧索硬化症(ALS),治疗和预防耳神经毒性和涉及谷氨酸毒性的眼病,以及治疗、预防或改善疼痛,作为抗癫痫药,作为抗躁狂抑郁药,作为局部麻醉药,作为抗心律失常药,以及治疗或预防糖尿病性神经病变和尿失禁。
  • NOVEL INHIBITORS
    申请人:Heiser Ulrich
    公开号:US20110092501A1
    公开(公告)日:2011-04-21
    The invention relates to novel pyrrolidine derivatives of formula (I): wherein R 1 , R 2 and R 3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    本发明涉及新颖的吡咯烷衍生物,其具有如下公式(I):其中R1、R2和R3如本文所述定义,作为谷氨酰胺环化酶(QC,EC 2.3.2.5)的抑制剂。谷氨酰胺环化酶催化N末端谷氨酰胺残基形成焦谷氨酸(5-氧代脯氨酸,pGlu*)的分子内环化,并释放氨,以及催化N末端谷氨酸残基形成焦谷氨酸的分子内环化,并释放水。
  • PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME
    申请人:Tanaka Keigo
    公开号:US20090082403A1
    公开(公告)日:2009-03-26
    Anti-fungal agent having excellent anti-fungal action physicochemical properties including safety and water solubility. Compound represented by formula (I), or salt thereof: wherein R 1 represents hydrogen, halogen, amino, R 11 —NH— wherein R 11 represents C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, or C 1-6 alkoxycarbonyl C 1-6 alkyl, R 12 —(CO)—NH— wherein R 12 represents C 1-6 alkyl group or C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkyl, hydroxy C 1-6 alkyl, cyano C 1-6 alkyl, C 1-6 alkoxy, or C 1-6 alkoxy C 1-6 alkyl or a phosphonoamino group; R 2 represents hydrogen, C 1-6 alkyl, amino, or a di C 1-6 alkylamino group or a phosphonoamino group; one of X and Y is nitrogen while the other is nitrogen or oxygen; ring A represents a 5- or 6-member heteroaryl ring or a benzene ring which may have a halogen atom or 1 or 2 C 1-6 alkyl groups; Z represents a single bond, a methylene group, an ethylene group, oxygen, sulfur, —CH 2 O—, —OCH 2 —, —NH—, —CH 2 NH—, —NHCH 2 —, —CH 2 S—, or —SCH 2 —; R 3 represents hydrogen or halogen or C 1-6 alkyl, C 3-8 cycloalkyl, C 6-10 aryl, a 5- or 6-member heteroaryl group or a 5- or 6-member nonaromatic heterocyclic group which may have 1 or 2 substituents; and R 4 represents hydrogen or halogen; provided that either R 1 or R 2 represents a phosphonoamino group.
    抗真菌剂具有优异的抗真菌作用物理化学性质,包括安全性和水溶性。化合物由式(I)表示,或其盐: 其中R1代表氢,卤素,氨基,R11—NH—其中R11代表C1-6烷基,羟基C1-6烷基,C1-6烷氧基C1-6烷基,或C1-6烷氧羰基C1-6烷基,R12—(CO)—NH—其中R12代表C1-6烷基或C1-6烷氧基C1-6烷基,C1-6烷基,羟基C1-6烷基,氰基C1-6烷基,C1-6烷氧基,或C1-6烷氧基C1-6烷基或磷酰氨基团;R2代表氢,C1-6烷基,氨基,或二C1-6烷基氨基团或磷酰氨基团;X和Y中的一个是氮,另一个是氮或氧;环A代表5-或6-成员杂芳基环或可能具有卤素原子或1或2个C1-6烷基基团的苯环;Z代表单键,亚甲基基团,乙烯基团,氧,硫,—CH2O—,—OCH2—,—NH—,—CH2NH—,—NHCH2—,—CH2S—,或—SCH2—;R3代表氢或卤素或C1-6烷基,C3-8环烷基,C6-10芳基,5-或6-成员杂芳基团或可能具有1或2个取代基的5-或6-成员非芳香杂环基;和R4代表氢或卤素;前提是R1或R2中的一个代表磷酰氨基团。
  • NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF
    申请人:Cho Hoon
    公开号:US20110269954A1
    公开(公告)日:2011-11-03
    The present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and the uses thereof. More specifically, the present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and a pharmaceutical composition comprising the same. The novel thiazolidinedione derivatives of formula (I) according to the present invention can be effectively used for the prevention or treatment of cardiovascular disease, gastrointestinal disease and renal disease by inhibiting the activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) that decomposes prostaglandins as well as useful for the prevention of hair loss and the stimulation of hair growth, and osteogenic stimulation and wound healing.
    本发明涉及由以下式(I)表示的新型噻唑烷二酮衍生物及其用途。更具体地说,本发明涉及由以下式(I)表示的新型噻唑烷二酮衍生物以及包含其的药物组合物。根据本发明的式(I)的新型噻唑烷二酮衍生物可以通过抑制分解前列腺素的15-羟基前列腺素脱氢酶(15-PGDH)的活性,有效用于预防或治疗心血管疾病、胃肠道疾病和肾脏疾病,同时也用于预防脱发和促进头发生长,以及促进骨生成和伤口愈合。
  • Structural optimization of super-gelators derived from naturally-occurring mannose and their morphological diversity
    作者:Fumiyasu Ono、Hisayuki Watanabe、Seiji Shinkai
    DOI:10.1039/c4ra03096f
    日期:——
    Mannose derivatives were synthesized as low molecular-weight gelators with various alkoxy substituents on the aromatic ring of methyl-4,6-O-benzilidene-α-D-mannopyranoside . Most of these mannose derivatives could gel in various solvents, such as octane, cyclohexane, toluene, ethylene glycol and ethanol solutions, at concentrations lower than 2.0 wt%. In particular, the critical gelation concentration
    合成了甘露糖衍生物作为低分子量胶凝剂,其在甲基-4,6- O-苯并亚甲基-α- D-甘露吡喃糖苷的芳环上具有各种烷氧基取代基。这些甘露糖衍生物中的大多数可以在各种溶剂(例如辛烷,环己烷,甲苯,乙二醇和乙醇溶液)中以低于2.0 wt%的浓度凝胶化。特别是甲基-4,6 - O-(4-丁氧基亚苄基)-α - D-甘露吡喃糖苷的临界胶凝浓度(CGC)(2)角鲨烷的含量仅为0.025 wt%,这是我们经历过的最低的CGC之一。通过FE-SEM,TEM和AFM对干凝胶的观察表明,甘露糖衍生物的烷氧基链的长度会影响凝胶的形态。此外,由被线性烷氧基官能化的甘露糖衍生物1-6形成的甲苯凝胶具有触变性。有趣的是,由甲基-4,6 - O-(4-十二烷氧基苄叉基)-α - D-甘露吡喃糖苷(6)(在芳环上具有最长的烷氧基链)形成的各种溶剂的凝胶均具有触变性。因此,我们证实了芳环上的烷氧基对这些甘露糖衍生物的胶凝特性产生了显着影响。
查看更多